$BOTY
LINGERIE FIGHTING CHAMPIONSHIPS, INC.

2023 Form 10-K Financial Statement

#000164033424001113 Filed on July 15, 2024

View on sec.gov

Income Statement

Concept 2023 2022
Revenue $117.7K $113.8K
YoY Change 3.45% 19.24%
Cost Of Revenue $68.92K $33.83K
YoY Change 103.72% -64.85%
Gross Profit $48.81K $79.97K
YoY Change -38.97% -9985.04%
Gross Profit Margin 41.46% 70.27%
Selling, General & Admin $62.46K $269.2K
YoY Change -76.8% -34.6%
% of Gross Profit 127.98% 336.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $272.4K $269.2K
YoY Change 1.18% -34.6%
Operating Profit -$223.6K -$189.2K
YoY Change 18.14% -54.12%
Interest Expense $287.5K $1.967M
YoY Change -85.39% 213.86%
% of Operating Profit
Other Income/Expense, Net $532.0K $1.967M
YoY Change -72.95% -163.22%
Pretax Income $308.5K $1.778M
YoY Change -82.65% -150.45%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $308.5K $1.778M
YoY Change -82.65% -150.45%
Net Earnings / Revenue 262.02% 1562.14%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.727B shares 3.575B shares
Diluted Shares Outstanding 10.57B shares 9.240B shares

Balance Sheet

Concept 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.300K $10.01K
YoY Change -47.05% -70.97%
Cash & Equivalents $5.300K $10.01K
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.300K $10.01K
YoY Change -47.05% -76.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.300K $10.01K
Total Long-Term Assets $0.00 $0.00
Total Assets $5.300K $10.01K
YoY Change -47.05% -76.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $652.6K $579.8K
YoY Change 12.57% 24.64%
Accrued Expenses $669.0K $442.9K
YoY Change 51.06% 91.03%
Deferred Revenue
YoY Change
Short-Term Debt $1.044M $924.7K
YoY Change 12.89% 15.62%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.204M $4.915M
YoY Change -14.45% -28.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.204M $4.915M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.204M $4.915M
YoY Change -14.45% -28.16%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.199M -$4.905M
YoY Change
Total Liabilities & Shareholders Equity $5.300K $10.01K
YoY Change -47.05% -76.16%

Cashflow Statement

Concept 2023 2022
OPERATING ACTIVITIES
Net Income $308.5K $1.778M
YoY Change -82.65% -150.45%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$150.2K -$87.99K
YoY Change 70.65% -66.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $145.4K 63.52K
YoY Change 128.97% -78.54%
NET CHANGE
Cash From Operating Activities -$150.2K -87.99K
Cash From Investing Activities $0.00 0.000
Cash From Financing Activities $145.4K 63.52K
Net Change In Cash -$4.714K -24.47K
YoY Change -80.74% -180.66%
FREE CASH FLOW
Cash From Operating Activities -$150.2K -$87.99K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Profit Loss
ProfitLoss
1679959 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-26602 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
99460 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63520 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34481 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5295 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10009 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001407704
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
51 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
51 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
51 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3896928536 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3711714036 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
333-148005
CY2023 dei Entity Registrant Name
EntityRegistrantName
LINGERIE FIGHTING CHAMPIONSHIPS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1399226
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
6955 North Durango Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1115-129
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89149
CY2023 dei City Area Code
CityAreaCode
702
CY2023 dei Local Phone Number
LocalPhoneNumber
505-0743
CY2023 dei Security12g Title
Security12gTitle
Common stock, par value $0.001 per share
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
740473 usd
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3954844036 shares
CY2023 dei Auditor Firm
AuditorFirmId
6920
CY2023 dei Auditor Location
AuditorLocation
Tampa, Florida
CY2023Q4 us-gaap Notes Payable
NotesPayable
340000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
340000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
64016 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
34800 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
703958 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
584730 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
51 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3896928536 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3711714036 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3896930 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1206572 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9302609 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4199107 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5295 usd
CY2023 us-gaap Revenues
Revenues
117722 usd
CY2022 us-gaap Revenues
Revenues
113802 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
68917 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
33831 usd
CY2023 us-gaap Gross Profit
GrossProfit
48805 usd
CY2022 us-gaap Gross Profit
GrossProfit
79971 usd
CY2023 us-gaap Salaries And Wages
SalariesAndWages
120000 usd
CY2022 us-gaap Salaries And Wages
SalariesAndWages
120000 usd
CY2023 us-gaap Professional Fees
ProfessionalFees
89918 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
78039 usd
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
62459 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71173 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
272377 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
269212 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-223572 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-189241 usd
CY2022 us-gaap Interest Expense
InterestExpense
335953 usd
CY2023 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
819489 usd
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2205153 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
532024 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
308452 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1679959 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
308452 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1679959 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3727444583 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3575418028 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10569820229 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9239631986 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6368687 usd
CY2022 boty Shares Of Common Stock Issued For Exercise Of Warrants Amount
SharesOfCommonStockIssuedForExerciseOfWarrantsAmount
116486 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1679959 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4572242 usd
CY2023 boty Shares Of Common Stock Issued For Exercise Of Warrants Amount
SharesOfCommonStockIssuedForExerciseOfWarrantsAmount
64683 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
308452 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4199107 usd
CY2023 us-gaap Profit Loss
ProfitLoss
308452 usd
CY2023 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-819489 usd
CY2022 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-2205153 usd
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
61894 usd
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
124904 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7500 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
16249 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
77500 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
226127 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
211049 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-150158 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87992 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
145444 usd
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
63520 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
145444 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4714 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24472 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10009 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023 boty Noncash Or Part Noncash Debt Discount From Derivative Liabilities
NoncashOrPartNoncashDebtDiscountFromDerivativeLiabilities
91111 usd
CY2022 boty Noncash Or Part Noncash Debt Discount From Derivative Liabilities
NoncashOrPartNoncashDebtDiscountFromDerivativeLiabilities
70520 usd
CY2023 boty Noncash Or Part Noncash Shares Of Common Stock Issued For Exercise Of Warrants
NoncashOrPartNoncashSharesOfCommonStockIssuedForExerciseOfWarrants
64683 usd
CY2022 boty Noncash Or Part Noncash Shares Of Common Stock Issued For Exercise Of Warrants
NoncashOrPartNoncashSharesOfCommonStockIssuedForExerciseOfWarrants
116486 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company continually evaluates its estimates and judgments. The Company bases its estimates and judgments on historical experience and other factors that it believes to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.</p>
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5295 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10009 usd
CY2023 us-gaap Revenues
Revenues
117722 usd
CY2022 us-gaap Revenues
Revenues
113802 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6842375646 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7550539808 shares
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1838806 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2634867 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5556666666 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2022 boty Number Of Shares Granted
NumberOfSharesGranted
282080000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0005
CY2022 boty Exercised
Exercised
-201613143 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0001
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5637133523 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2023 boty Number Of Shares Granted
NumberOfSharesGranted
184883994 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0005
CY2023 boty Exercised
Exercised
-227308705 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0001
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5594708812 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0002
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
185214500 shares
CY2023 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
227308705 shares
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
176411500 shares
CY2022 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
201613143 shares
CY2023 boty Expected Term
ExpectedTerm
P2Y18D
CY2022 boty Expected Term
ExpectedTerm
P2Y11M23D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
452108 usd
CY2023Q4 boty Closing Market Price
ClosingMarketPrice
0.0002
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5594708812 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5637133523 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1093440 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1683773 shares
CY2023Q4 us-gaap Notes Payable
NotesPayable
340000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
340000 usd
CY2021Q1 boty Warrants Price Per Share
WarrantsPricePerShare
0.002
CY2021Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
35000 usd
CY2021Q1 boty Warrants Derivative Amount
WarrantsDerivativeAmount
265000 usd
CY2021Q1 boty Debt Instrument Aggregate Discount
DebtInstrumentAggregateDiscount
300000 usd
CY2021Q4 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
50000000 shares
CY2021Q4 boty Warrants Price Per Share
WarrantsPricePerShare
0.0008
CY2021Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
9000 usd
CY2021Q4 boty Warrants Derivative Amount
WarrantsDerivativeAmount
31000 usd
CY2021Q4 boty Debt Instrument Aggregate Discount
DebtInstrumentAggregateDiscount
40000 usd
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
703958 usd
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
584730 usd
CY2023 us-gaap Interest And Debt Expense
InterestAndDebtExpense
173325 usd
CY2022 us-gaap Interest And Debt Expense
InterestAndDebtExpense
158249 usd
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
530405 usd
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
357080 usd
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y6M18D
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
4892985 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
19719 usd
CY2022 boty Reduction Of Derivative Liabilities From Exercise Of Warrants
ReductionOfDerivativeLiabilitiesFromExerciseOfWarrants
-116485 usd
CY2022 boty Addition Of New Derivative Liabilities Upon Issuance Of Warrants As Debt Discount
AdditionOfNewDerivativeLiabilitiesUponIssuanceOfWarrantsAsDebtDiscount
43801 usd
CY2022 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
125714 usd
CY2022 boty Gain Loss On Change In Fair Value Of The Derivative Liability
GainLossOnChangeInFairValueOfTheDerivativeLiability
-2330867 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2634867 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
29111 usd
CY2023 boty Reduction Of Derivative Liabilities From Exercise Of Warrants
ReductionOfDerivativeLiabilitiesFromExerciseOfWarrants
-64683 usd
CY2023 boty Addition Of New Derivative Liabilities Upon Issuance Of Warrants As Debt Discount
AdditionOfNewDerivativeLiabilitiesUponIssuanceOfWarrantsAsDebtDiscount
59000 usd
CY2023 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
101123 usd
CY2023 boty Gain Loss On Change In Fair Value Of The Derivative Liability
GainLossOnChangeInFairValueOfTheDerivativeLiability
-920612 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1838806 usd
CY2023 boty Day One Loss Due To Derivative Liabilities On Convertible Notes And Warrant
DayOneLossDueToDerivativeLiabilitiesOnConvertibleNotesAndWarrant
101123 usd
CY2022 boty Day One Loss Due To Derivative Liabilities On Convertible Notes And Warrant
DayOneLossDueToDerivativeLiabilitiesOnConvertibleNotesAndWarrant
125714 usd
CY2023 boty Gain Loss On Change In Fair Value Of Derivative Liabilities On Convertible Notes And Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilitiesOnConvertibleNotesAndWarrants
-920612 usd
CY2022 boty Gain Loss On Change In Fair Value Of Derivative Liabilities On Convertible Notes And Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilitiesOnConvertibleNotesAndWarrants
-2330867 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-819489 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-2205153 usd
CY2023 us-gaap Salaries And Wages
SalariesAndWages
120000 usd
CY2023 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
20540 usd
CY2022 us-gaap Salaries And Wages
SalariesAndWages
120000 usd
CY2022 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
42500 usd
CY2023Q4 boty Related Party Transaction Amounts Of Transaction Accounts Payable
RelatedPartyTransactionAmountsOfTransactionAccountsPayable
642128 usd
CY2022Q4 boty Related Party Transaction Amounts Of Transaction Accounts Payable
RelatedPartyTransactionAmountsOfTransactionAccountsPayable
542668 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4856636 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4345599 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1019894 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
912576 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1019894 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
912576 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
107318 usd
CY2022 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
110291 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4900000 usd
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
In accordance with Section 382 of the U.S. Internal Revenue Code, the usage of the Company’s net operating loss carry forwards is subject to annual limitations following greater than 50% ownership changes. Tax returns for the years ended 2014 through 2023 are subject to review by the tax authorities
CY2023 dei Auditor Name
AuditorName
Astra Audit & Advisory, LLC

Files In Submission

Name View Source Status
0001640334-24-001113-index-headers.html Edgar Link pending
0001640334-24-001113-index.html Edgar Link pending
0001640334-24-001113.txt Edgar Link pending
0001640334-24-001113-xbrl.zip Edgar Link pending
boty-20231231.xsd Edgar Link pending
boty_10k.htm Edgar Link pending
boty_10kimg2.jpg Edgar Link pending
boty_10kimg4.jpg Edgar Link pending
boty_ex103.htm Edgar Link pending
boty_ex104.htm Edgar Link pending
boty_ex104img1.gif Edgar Link pending
boty_ex104img8.jpg Edgar Link pending
boty_ex104img9.jpg Edgar Link pending
boty_ex105.htm Edgar Link pending
boty_ex105img1.gif Edgar Link pending
boty_ex107.htm Edgar Link pending
boty_ex109.htm Edgar Link pending
boty_ex311.htm Edgar Link pending
boty_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
boty-20231231_lab.xml Edgar Link unprocessable
boty-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
boty_10k_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
boty-20231231_cal.xml Edgar Link unprocessable
boty-20231231_def.xml Edgar Link unprocessable